Department of Physiology and Pharmacology, Alberta Children's Hospital Research Institute, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Department of Neurology and the Molecular Pharmacology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Mol Brain. 2019 Nov 27;12(1):98. doi: 10.1186/s13041-019-0524-6.
We have examined the regulation of mutually exclusive Cav2.2 exon 37a and b variants by the mouse μ-opioid receptor (mMOR) C-terminal splice variants 1, 1C and 1O in tsA-201 cells. Electrophysiological analyses revealed that both channel isoforms exhibit DAMGO-induced voltage-dependent (Gβγ-mediated) inhibition and its recovery by voltage pre-pulses, as well as a voltage-independent component. However, the two channel isoforms differ in their relative extent of voltage-dependent and independent inhibition, with Cav2.2-37b showing significantly more voltage-dependent inhibition upon activation of the three mMOR receptors studied. In addition, coexpression of either mMOR1 or mMOR1C results in an agonist-independent reduction in the peak current density of Cav2.2-37a channels, whereas the peak current density of Cav2.2-37b does not appear to be affected. Interestingly, this decrease is not due to an effect on channel expression at the plasma membrane, as demonstrated by biotinylation experiments. We further examined the mechanism underlying the agonist-independent modulation of Cav2.2-37a by mMOR1C. Incubation of cells with pertussis toxin did not affect the mMOR1C mediated inhibition of Cav2.2-37a currents, indicating a lack of involvement of Gi/o signaling. However, when a Src tyrosine kinase inhibitor was applied, the effect of mMOR1C was lost. Moreover, when we recorded currents using a Cav2.2-37a mutant in which tyrosine 1747 was replaced with phenylalanine (Y1747F), the agonist independent effects of mMOR1C were abolished. Altogether our findings show that Cav2.2-37a and Cav2.2-37b isoforms are subject to differential regulation by C-terminal splice variants of mMORs, and that constitutive mMOR1C activity and downstream tyrosine kinase activity exert a selective inhibition of the Cav2.2-37a splice variant, an N-type channel isoform that is highly enriched in nociceptors. Our study provides new insights into the roles of the MOR full-length C-terminal variants in modulating Cav2.2 channel isoform activities.
我们研究了小鼠μ-阿片受体(mMOR)C 端剪接变体 1、1C 和 1O 对相互排斥的 Cav2.2 外显子 37a 和 b 变体的调节作用在 tsA-201 细胞中。电生理分析显示,两种通道同工型均表现出 DAMGO 诱导的电压依赖性(Gβγ介导)抑制及其通过电压前脉冲的恢复,以及非电压依赖性成分。然而,两种通道同工型在电压依赖性和非依赖性抑制的相对程度上存在差异,Cav2.2-37b 在研究的三种 mMOR 受体激活时表现出显著更多的电压依赖性抑制。此外,表达任何一种 mMOR1 或 mMOR1C 都会导致 Cav2.2-37a 通道的峰电流密度产生激动剂非依赖性降低,而 Cav2.2-37b 的峰电流密度似乎不受影响。有趣的是,这种降低不是由于在质膜上对通道表达的影响,如生物素化实验所示。我们进一步研究了 mMOR1C 对 Cav2.2-37a 的激动剂非依赖性调节的机制。用百日咳毒素孵育细胞不会影响 mMOR1C 介导的 Cav2.2-37a 电流抑制,表明 Gi/o 信号没有参与。然而,当应用Src 酪氨酸激酶抑制剂时,m MOR1C 的作用消失了。此外,当我们使用 Cav2.2-37a 突变体(其中酪氨酸 1747 被苯丙氨酸取代(Y1747F))记录电流时,m MOR1C 的激动剂非依赖性作用被消除。总之,我们的发现表明 Cav2.2-37a 和 Cav2.2-37b 同工型受到 mMOR C 端剪接变体的差异调节,而组成型 mMOR1C 活性和下游酪氨酸激酶活性对 Cav2.2-37a 剪接变体(一种高度富集在伤害感受器中的 N 型通道同工型)具有选择性抑制作用。我们的研究为 MOR 全长 C 端变体在调节 Cav2.2 通道同工型活性中的作用提供了新的见解。